Regulation of therapeutic goods in the United States |
---|
![]() |
Prescription drugs Over-the-counter drugs |
The Center for Drug Evaluation and Research (CDER, pronounced "see'-der") is a division of the U.S. Food and Drug Administration (FDA) that monitors most drugs as defined in the Food, Drug, and Cosmetic Act. Some biological products are also legally considered drugs, but they are covered by the Center for Biologics Evaluation and Research. The center reviews applications for brand name, generic, and over the counter pharmaceuticals, manages US current Good Manufacturing Practice (cGMP) regulations for pharmaceutical manufacturing, determines which medications require a medical prescription, monitors advertising of approved medications, and collects and analyzes safety data about pharmaceuticals that are already on the market.
CDER receives considerable public scrutiny, and thus implements processes that tend toward objectivity and tend to isolate decisions from being attributed to specific individuals. The decisions on approval will often make or break a small company's stock price[citation needed] (e.g., Martha Stewart and Imclone), so the markets closely watch CDER's decisions.
The center has around 1,300 employees in "review teams" that evaluate and approve new drugs. Additionally, the CDER employs a "safety team" with 72 employees to determine whether new drugs are unsafe or present risks not disclosed in the product's labeling.[citation needed]
The FDA's budget for approving, labeling, and monitoring drugs is roughly $290 million per year[citation needed]. The safety team monitors the effects of more than 3,000 prescription drugs on 200 million people with a budget of about $15 million a year[citation needed].
Patrizia Cavazzoni is the current director of CDER.[1]